drugset / Trial / NCT00403845

Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00403845

Phase 2 Completed 50 enrolled Novartis
RandomizedCrossoverDouble-blindTreatment

Summary

The study was designed to obtain data about the efficacy and safety of 3 doses of indacaterol (150, 300, and 600 µg) in Japanese patients with chronic obstructive pulmonary disease (COPD) so that optimal dose(s) could be chosen for testing in later studies.

Timeline

Start
2006-12
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Indacaterol Other / unclassified 150 ug Inhaled
Subject Indacaterol Other / unclassified 300 ug Inhaled
Subject Indacaterol Other / unclassified 600 ug Inhaled